Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is shed in saliva, sputum, and feces of the novel coronavirus disease 2019 (COVID-19) patients, and SARS-CoV-2 RNA has been detected in sewage. Thus, many regions worldwide have implemented the measurement of SARS-CoV-2 RNA in sewage as a monitoring tool for COVID-19 prevalence. Here, we report the monitoring of two wastewater treatment plants in Tokyo from May 2020 to June 2022 using a fully automated genetic testing method for the solid fraction of sewage. We found that SARS-CoV-2 sewage monitoring using the Panther System with the Aptima SARS-CoV-2 Assay Kit is an effective method of qualitative monitoring. Furthermore, spike gene mutations (N501Y, L452R, E484A) by real-time PCR using test residues were detected in some samples, which reflected the epidemic status. Nevertheless, our findings demonstrate that the use of a fully automated testing platform is effective for SARS-CoV-2 RNA detection in the solid fraction of sewage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11502634 | PMC |
| http://dx.doi.org/10.1007/s13337-024-00880-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Virologic characteristics of SARS-CoV-2 infection across evolving omicron subvariants.
JCI Insight
September 2025
Ragon Institute of Mass General Brigham, Cambridge, United States of America.
Background: The SARS-CoV-2 virus has evolved subvariants since the emergence of the omicron variant in 2021. Whether these changes impact viral shedding and transmissibility is not known.
Methods: POSITIVES is a prospective longitudinal cohort of individuals with mild SARS-CoV-2 infection.
[Severe acute respiratory syndrome coronavirus 2 infection and post COVID-19 condition: the theory of immune pathology].
Zhonghua Bing Li Xue Za Zhi
September 2025
Department of Pathology, Changhai Hospital, Navy Medical University, Shanghai 200433, China.
Next-Generation Nanoparticle-Enabled mRNA Vaccines in the Treatment of COVID-19.
Crit Rev Ther Drug Carrier Syst
September 2025
The emergence of messenger ribonucleic acid (mRNA) vaccines as an alternative platform to traditional vaccines has been accompanied by advances in nanobiotechnology, which have improved the stability and delivery of these vaccines through novel nanoparticles (NPs). Specifically, the development of NPs for mRNA delivery has facilitated the loading, protection and release of mRNA in the biological microenvironment, leading to the stimulation of mRNA translation for effective intervention strategies. Intriguingly, two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), have been permitted for emergency usage authorization to prevent COVID-19 infection by USFDA.
View Article and Find Full Text PDFDiscovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus.
PLoS Pathog
September 2025
State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Coronavirus, a large family of positive-sense RNA viruses, are responsible for both mild and severe respiratory illnesses, ranging from the common cold to life-threatening conditions. Despite significant advances in vaccine and antiviral development, the high mutability of human coronaviruses (HCoVs), such as SARS-CoV-2, presents a major challenge in treating these infections. Effective, broad-spectrum antiviral drugs are urgently needed to address both current and future HCoV outbreaks.
View Article and Find Full Text PDFImmune signatures of SARS-CoV-2 infection resolution in human lung tissues.
PLoS Pathog
September 2025
Department of Virology, Immunology, and Microbiology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.
While human autopsy samples have provided insights into pulmonary immune mechanisms associated with severe viral respiratory diseases, the mechanisms that contribute to a clinically favorable resolution of viral respiratory infections remain unclear due to the lack of proper experimental systems. Using mice co-engrafted with a genetically matched human immune system and fetal lung xenograft (fLX), we mapped the immunological events defining successful resolution of SARS-CoV-2 infection in human lung tissues. Viral infection is rapidly cleared from fLX following a peak of viral replication, histopathological manifestations of lung disease and loss of AT2 program, as reported in human COVID-19 patients.
View Article and Find Full Text PDF